Haleon cuts outlook to 2.5 percent: what it means for Haleon stock

Published on 10/29/2026 at 13:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q3 revenue reached GBP 2,868 million. For Haleon stock this means a GBP 500 million buyback and a sharper growth focus.

Category trends shape the outlook

Oral Health organic revenue grew 8.8 percent in the three months ended September 30, 2026.
Respiratory Health organic revenue declined 2.0 percent in the third quarter of 2026.
Haleon scheduled its fiscal year 2026 results for February 25, 2027.

Haleon, GB00BMX86B70, Illustration mit AI erstellt.

Haleon (ISIN GB00BMX86B70) set its 2026 organic revenue-growth outlook at 2.5 percent on October 29, 2026, according to Haleon. The revision followed third-quarter organic revenue growth of 2.6 percent and came alongside a GBP 500 million share-buyback allocation.

Q3 growth shows a split picture

The three months ended September 30, 2026, produced reported revenue of GBP 2,868 million, while price contributed 2.1 percent and volume and mix added 0.5 percent. The company said weaker cough, cold and flu consumption reduced orders in North America and contributed to the softer group result.

Oral Health provided the strongest counterweight. Organic revenue in that category increased 8.8 percent, supported by Sensodyne and parodontax, while International revenue grew 6.9 percent. Respiratory Health moved in the opposite direction, with organic revenue declining 2.0 percent in the quarter.

What does the outlook cut mean?

The updated growth view leaves Haleon relying more heavily on category execution and cost productivity. Management maintained its expectation for high-single-digit adjusted operating profit growth at constant currency, while the Brazil go-to-market acceleration is expected to reduce fourth-quarter net revenue by GBP 15 million to GBP 20 million, according to Reuters.

The buyback offers a capital-return signal while the operating picture remains uneven. Haleon said the additional purchases are expected to be completed by the publication of its fiscal year results in February 2027, with the company also citing a raw-material classification change affecting Centrum over-the-counter products in China.

Results dates set for 2027

Haleon's published timetable places its fiscal year 2026 results on February 25, 2027, followed by the first-quarter 2027 trading statement on April 29, 2027. These dates give investors the next formal checkpoints for growth delivery, category recovery and the buyback timetable.

Stock trades after the update

Haleon was trading at EUR 3.85 at Lang & Schwarz on October 29, 2026 at 1:05 p.m. CEST. The quote reflects the market's immediate reference point after the trading statement, while the company-level figures show why Oral Health and the North American turnaround matter for the next reporting cycle. The further course of trading is shown by the continuously updated real-time quote of Haleon stock.